Rapid Novor Inc. and MAbSilico announced that they have partnered to provide the world's first AI-driven HDX-MS epitope mapping service for antibody development. By seamlessly integrating experimental data with predictive analytics derived from AI-based computational modeling, researchers can gain a comprehensive understanding of antibody structure, dynamics, and interactions.